Immunocellular Therapeutics LTD (IMUC) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
30721 RUSSELL RANCH ROAD WESTLAKE VILLAGE, CA 91362 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 6/30/2018 Q2 | 3/31/2018 Q1 | 12/31/2017 Q4 | 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | 12/31/2016 Q4 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 2,853 | 5,027 | 6,630 | 6,005 | 1,814 | 5,341 | 11,437 | ||
| Cash and cash equivalents | 2,853 | 5,027 | 6,630 | 6,005 | 1,814 | 5,341 | 11,437 | ||
| Receivables | 487 | ||||||||
| Prepaid expense | 1,302 | 1,186 | |||||||
| Other current assets | 490 | 138 | 379 | 711 | 2,589 | 494 | 791 | ||
| Total current assets: | 3,829 | 5,164 | 7,009 | 6,716 | 4,403 | 7,138 | 13,415 | ||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 0 | 0 | 1 | 60 | 77 | 93 | 110 | ||
| Prepaid expense | 1,138 | 1,310 | |||||||
| Deposits noncurrent assets | 1,921 | 1,956 | |||||||
| Other undisclosed noncurrent assets | 331 | 216 | 100 | ||||||
| Total noncurrent assets: | 0 | 0 | 1 | 60 | 408 | 3,369 | 3,475 | ||
| TOTAL ASSETS: | 3,829 | 5,165 | 7,009 | 6,776 | 4,811 | 10,507 | 16,890 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 402 | 1,493 | 2,361 | 7,299 | 7,720 | 2,159 | 3,239 | ||
| Accounts payable | 84 | 1,125 | 1,775 | 3,766 | 4,251 | 915 | 1,342 | ||
| Accrued liabilities | 161 | 215 | 296 | 3,098 | 3,268 | 1,010 | 787 | ||
| Employee-related liabilities | 156 | 153 | 291 | 435 | 202 | 234 | 1,110 | ||
| Total current liabilities: | 402 | 1,493 | 2,361 | 7,299 | 7,720 | 2,159 | 3,239 | ||
| Noncurrent Liabilities | |||||||||
| Other undisclosed noncurrent liabilities | 28 | 7,869 | 7,519 | ||||||
| Total noncurrent liabilities: | 28 | 7,869 | 7,519 | ||||||
| Total liabilities: | 402 | 1,493 | 2,361 | 7,299 | 7,748 | 10,028 | 10,758 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 3,427 | 3,672 | 4,648 | (523) | (2,937) | 479 | 6,132 | ||
| Common stock | 4 | 4 | 4 | 2 | 0 | 0 | 0 | ||
| Additional paid in capital | 121,199 | 121,136 | 121,088 | 115,487 | 102,720 | 102,527 | 102,355 | ||
| Accumulated deficit | (117,775) | (117,469) | (116,444) | (116,012) | (105,658) | (102,048) | (96,223) | ||
| Total stockholders' equity: | 3,427 | 3,672 | 4,648 | (523) | (2,937) | 479 | 6,132 | ||
| TOTAL LIABILITIES AND EQUITY: | 3,829 | 5,165 | 7,009 | 6,776 | 4,811 | 10,507 | 16,890 | ||
Income Statement (P&L) ($ in thousands) Annual | Quarterly
| 6/30/2018 Q2 | 3/31/2018 Q1 | 12/31/2017 Q4 | 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | 12/31/2016 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (307) | (1,025) | (432) | (3,901) | (11,342) | (5,479) | (7,319) | |
| Other undisclosed operating loss | (422) | |||||||
| Operating loss: | (307) | (1,025) | (432) | (3,901) | (11,342) | (5,479) | (7,319) | |
| Nonoperating income (Investment Income, Nonoperating) | 0 | 0 | 0 | 0 | 443 | 107 | 1,773 | |
| Interest and debt expense | 7,289 | (453) | (423) | |||||
| Loss from continuing operations before equity method investments, income taxes: | (307) | (1,025) | (431) | (3,901) | (3,609) | (5,825) | (5,969) | |
| Other undisclosed loss from continuing operations before income taxes | (356) | |||||||
| Net loss attributable to parent: | (307) | (1,025) | (431) | (3,901) | (3,609) | (5,825) | (6,325) | |
| Other undisclosed net loss available to common stockholders, basic | (1,191) | (2,178) | ||||||
| Net loss available to common stockholders, diluted: | (307) | (1,025) | (1,623) | (6,079) | (3,609) | (5,825) | (6,325) | |
Comprehensive Income ($ in thousands)Annual | Quarterly
| 6/30/2018 Q2 | 3/31/2018 Q1 | 12/31/2017 Q4 | 9/30/2017 Q3 | 6/30/2017 Q2 | 3/31/2017 Q1 | 12/31/2016 Q4 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (307) | (1,025) | (431) | (3,901) | (3,609) | (5,825) | (6,325) | |
| Comprehensive loss, net of tax, attributable to parent: | (307) | (1,025) | (431) | (3,901) | (3,609) | (5,825) | (6,325) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.